Evidence map›Paper›PMID 35677307›Full record

ArticleFrontiers in bioengineering and biotechnology2022

Preparation and Characterization of Site-Specific Fatty Chain-Modified Recombinant Human Granulocyte Colony Stimulating Factor.

Xu-Dong Wang, Wei-Jia Yu, Jia-Hui Liu, Jie Du, Kang-Nan Chen, Qin-Qin Hu, Wen-Long Sun, Guo-Qing Ying

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xu-Dong WangCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Wei-Jia YuCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Jia-Hui LiuCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Jie DuCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Kang-Nan ChenCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Qin-Qin HuCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Wen-Long SunInstitute of Biomedical Research, School of Life Sciences, Shandong University of Technology, Zibo, China.
Guo-Qing YingCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The clinical use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) is limited by its short serum half-life. In this study, a long-acting strategy for site-specific modification of rhG-CSF with 1-pentadecyl-1H-pyrrole-2,5-dione (C15 fatty chain-maleimide, C15-MAL) was studied in mixed DMSO-aqueous solutions. The factors influencing the conjugation reaction were investigated and optimized, and a high yield of the desired product (C15-rhG-CSF) was achieved. Subsequently, C15-rhG-CSF product was efficiently purified using preparative liquid chromatography, and further characterized. Circular dichroism spectroscopy analysis showed that the secondary structure of C15-rhG-CSF had no significant difference from unmodified rhG-CSF. C15-rhG-CSF retained 87.2% of

Indexed as

fatty chainfatty chain modificationlong-acting rhG-CSFrecombinant human granulocyte colony stimulating factorrhG-CSFsite-specific modificationthiol modification

Identifiers

PMID35677307
PMCPMC9168434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.